{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-046707","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2024-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.454164+00:00","generated_at":"2026-05-29T22:43:59.665134+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Kairos Pharma approved for dual listing on Upstream; trading starts Nov 26","bullets":["Approved to dual list shares on Upstream, a MERJ Exchange market and global trading app.","Trading begins November 26, 2024 at 10:00 a.m. ET under ticker 'KAPA'.","Dual listing aims to access global investor base outside U.S., unlock liquidity, enhance price discovery.","CEO John Yu says listing supports shareholder value and advancement of lead drug ENV105 in cancer trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-046707","json":"https://secwatch.observer/filing/0001493152-24-046707.json","markdown":"https://secwatch.observer/filing/0001493152-24-046707.md","text":"https://secwatch.observer/filing/0001493152-24-046707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315224046707/0001493152-24-046707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315224046707/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:43:59.665134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}